S. Karger AG

SHERPA: Unknown

People

  1. O'Reilly
    O'Reilly
  2. Panageas
    Panageas
  3. Scheinberg
    Scheinberg

Groups

  1. Department of Medicine (9)
  2. Solid Tumor Oncology Division (9)
  3. Thoracic Oncology (9)
  4. Adult Leukemia (1)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1)
  6. Biostatistics Service (1)
  7. Center for Hematologic Malignancies (1)
  8. Epidemiology and Biostatistics (1)
  9. GSK Faculty (1)
  10. Hematologic Malignancies Research (1)
Search Within
  1. "Matthew Hellmann"
Formats
  1. Meeting Abstract (9)
Groups
  1. Department of Medicine (9)
  2. Solid Tumor Oncology Division (9)
  3. Thoracic Oncology (9)
  4. Adult Leukemia (1)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1)
  6. Biostatistics Service (1)

More Groups

People
  1. Matthew Hellmann (9)
  2. David Scheinberg (1)
  3. Katherine Panageas (1)
  4. Margaret Callahan (1)
  5. Naiyer Rizvi (1)
  6. Richard O'Reilly (1)

More People

Years
  1. 2023 (1)
  2. 2022 (1)
  3. 2021 (1)
  4. 2020 (2)
  5. 2018 (1)
  6. 2017 (2)

More Years

Publications
  1. Oncology Research and Treatment (9)

Results (9)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Neopeptide diversity and similarity to the unmutated immunopeptidome is associated with response to immune checkpoint blockade therapy
    Meeting Abstract

    Klatt, M.; Molvi, Z.; Panageas, K.; Wells, D.; Hellmann, M.; Merghoub, T.; Wolchok, J.; O'Reilly, R.; Keller, U.; Scheinberg, D.
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Early circulating tumour DNA (ctDNA) dynamics for predicting and monitoring response to immunotherapy(IO) vs chemotherapy (CT) in patients with 1L metastatic (m) NSCLC: Analyses from the phase 3 MYSTIC trial
    Meeting Abstract

    Peters, S.; Rizvi, N.; Kuziora, M.; Lai, Z.; Shrestha, Y.; Dey, A.; Barrett, J. C.; Scheuring, U.; Poole, L.; Abbosh, C.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227
    Meeting Abstract

    Schumann, C.; Paz-Ares, L.; Ciuleanu, T. E.; Lee, J. S.; Urban, L.; Caro, R. B.; Park, K.; Sakai, H.; Ohe, Y.; Nishio, M.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) + ipilimumab (IPI) versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1
    Meeting Abstract

    Thomas, M.; Ramalingam, S. S.; Ciuleanu, T. E.; Pluzanski, A.; Lee, J. S.; Schenker, M.; BernabeĢ Caro, R.; Lee, K. H.; Zurawski, B.; Audigier-Valette, C.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Nivolumab (N) plus low-dose ipilimumab (I) vs platinum-doublet chemotherapy (Chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): Checkmate 227 part 1 final analysis
    Meeting Abstract

    Reck, M.; Peters, S.; Ramalingam, S.; Paz-Ares, L.; Caro, R. B.; Zurawski, B.; Kim, S. W.; Alexandru, A.; Lupinacci, L.; Jitnenez, E. D.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • CheckMate 227: Nivolumab (Nivo) + ipilimumab (Ipi) vs platinum-doublet chemotherapy (Chemo) as first-line treatment for advanced non-small cell lung cancer (NSCLC) with high tumor mutational burden (TMB)
    Meeting Abstract

    Reck, M.; Hellmann, M. D.; Paz-Ares Rodriguez, L.; Ramalingam, S. S.; Brahmer, J.; O'Byrne, K. J.; Bhagavatheeswaran, P.; Nathan, F.; Borghaei, H.
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Evaluation of nivolumab (nivo) alone and in combination with ipilimumab (ipi) in patients (pts) with advanced (adv) small-cell lung cancer (SCLC): First report of a randomized expansion cohort from the CheckMate 032 trial
    Meeting Abstract

    Atmaca, A.; Hellmann, M. D.; Ott, P. A.; Zugazagoitia, J.; Ready, N.; Hann, C. L.; De Braud, F.; Antonia, S.; Ascierto, P.; Moreno, V.; more...
    Oncology Research and Treatment (2017)

    Fulltext@MSK | Save
  • Tumor mutation burden (TMB) is associated with improved efficacy of atezolizumab in 1L and 2L+ NSCLC patients
    Meeting Abstract

    Griesinger, F.; Kowanetz, M.; Zou, W.; Shames, D. S.; Cummings, C. A.; Rizvi, N. A.; Spira, A.; Frampton, G.; Leveque, V.; Flynn, S.; more...
    Oncology Research and Treatment (2017)

    Fulltext@MSK | Save
  • CheckMate 017 and 057 studies of nivolumab vs docetaxel in patients with advanced NSCLC: 2-year-update and exploratory cytokine profile analyses
    Meeting Abstract

    Eberhardt, W. E. E.; Borghaei, H.; Brahmer, J. R.; Horn, L.; Ready, N.; Steins, M.; Felip, E.; Paz-Ares, L. G.; Arrieta, O.; Barlesi, F.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save